NK cell therapy stock poised for growth By Investing.com
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) is a clinical-stage biotechnology company that has captured the attention of investors and analysts alike with its innovative approach to developing natural killer (NK) cell-based therapies for autoimmune diseases and cancers. As the company progresses through critical stages of development, it faces both significant opportunities and challenges in the competitive landscape of immunotherapy.
Company Overview
Artiva Biotherapeutics specializes in advancing NK cell therapies, with a particular focus on treating autoimmune diseases. The company’s lead product, AlloNK, utilizes unengineered NK cells derived from cord blood, combined with flu/cy preconditioning and an anti-CD20 antibody. This…
